Anna Dodero

Fondazione IRCCS Istituto Nazionale dei Tumori — Italy

Medicine · Health Sciences

26h-index2.6kcitations174works5.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(100), CAR-T cell therapy research(51), Chronic Lymphocytic Leukemia Research(50), Hematopoietic Stem Cell Transplantation(28), T-cell and Retrovirus Studies(26)

Publications174 total

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study
Blood·2025
Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis
Blood Advances·2025· 1 citedOpen Access
Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes
British Journal of Haematology·2025· 1 citedOpen Access
350 | PATIENTS WITH RELAPSED/REFRACTORY PMBCL HAVE BETTER SURVIVAL WHEN THE SALVAGE STRATEGY INCLUDES CAR T‐CELLS: AN ANALYSIS OF THE REPRIME‐FIL AND THE CART‐SIE STUDIES
Hematological Oncology·2025Open Access
51 | LONG‐TERM BENEFIT AND MOLECULAR FEATURES OF PATIENTS WITH HCV‐ASSOCIATED INDOLENT LYMPHOMAS TREATED WITH DIRECT‐ACTING ANTIVIRALS: 6‐YEAR FOLLOW‐UP OF THE FIL_BArT STUDY
Hematological Oncology·2025Open Access
314 | ISOLATED CENTRAL NERVOUS SYSTEM RELAPSE AFTER CAR‐T CELL INFUSION IN LARGE B‐CELL LYMPHOMAS: AN ANALYSIS FROM THE ITALIAN CART‐SIE STUDY
Hematological Oncology·2025Open Access
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study
Haematologica·2025· 3 citedOpen Access
Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study
Blood·2024· 1 citedOpen Access
Carfilzomib, lenalidomide, dexamethasone (<scp>KRD</scp>) in <scp>BTKi</scp> relapsed or refractory mantle cell lymphoma: A phase <scp>II</scp> study from Fondazione Italiana Linfomi
British Journal of Haematology·2024Open Access
Secondary primary malignancies after <scp>CD‐19</scp> directed <scp>CAR</scp>‐T‐cell therapy in lymphomas: A report from the Italian <scp>CART</scp>‐<scp>SIE</scp> study
British Journal of Haematology·2024· 9 citedOpen Access
Polatuzumab vedotin, venetoclax, and an <scp>anti‐CD20</scp> monoclonal antibody in relapsed/refractory B‐cell <scp>non‐Hodgkin</scp> lymphoma
American Journal of Hematology·2024· 11 citedOpen Access
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
Leukemia·2024· 27 citedOpen Access
Monocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma
Blood Advances·2024· 23 citedOpen Access
Prognostic impact of pretreatment cell‐free <scp>DNA</scp> concentration in newly diagnosed peripheral T‐cell lymphomas
British Journal of Haematology·2024· 2 citedOpen Access
A Novel Model Combining Circulating Absolute Monocyte Counts and a Four-Gene Monocyte Signature in Leukapheresis Identifies Lymphoma Patients at Very High Risk of Progression after Tisagenlecleucel or Axicabtagene Ciloleucel Therapy
Blood·2023· 1 cited
Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study
Blood·2023Open Access
Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study
Blood·2023Open Access
Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study
Blood·2023Open Access
Prognostic Impact of Pre-Treatment Cell-Free DNA Concentration in Newly Diagnosed Peripheral T-Cell Lymphomas
Blood·2023
Outcome after chimeric antigen receptor (<scp>CAR</scp>) T‐cell therapy failure in large B‐cell lymphomas
British Journal of Haematology·2023· 21 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Paolo Corradini(40), Lucia Farina(18), Cristiana Carniti(14), Francesca Patriarca(13), Alessandro Rambaldi(13), Anna Guidetti(13), Alessandro M. Gianni(12), Corrado Tarella(11), Annalisa Chiappella(11), Francesco Spina(9), Carmelo Carlo‐Stella(9), Rosalba Miceli(8), Martina Pennisi(8), Marco Bregni(7), Attilio Olivieri(7), Fabio Ciceri(7), Vittorio Montefusco(7), Franco Narni(6), Fabio Benedetti(6), Francesco Maura(6)